Problems › We Keep Discounting to Win Deals › Healthcare Providers
Routine discounting on value-based contracts is usually a proof problem around cost per episode and an incentive problem, and almost never a price problem. The version of this question that applies to healthcare providers is not the generic one. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — so an answer that ignores cost per episode will be confidently wrong. The analysis has to start from payer mix and panel size rather than from revenue.
Routine discounting on value-based contracts is usually a proof problem around cost per episode and an incentive problem, and almost never a price problem. The version of this question that applies to healthcare providers is not the generic one. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — so an answer that ignores cost per episode will be confidently wrong. The analysis has to start from payer mix and panel size rather than from revenue.
When discounting becomes normal in payer negotiations, the contracted rate has effectively been reset to the discounted level and the base rate in the value-based contract is decoration. That has a cost beyond margin on the 38,000 attributed lives: it tells payers what the operator will accept under downside risk, and it is very hard to reverse without losing panel size.
The causes are consistent. Cost per episode is not known or proven for the attributed lives, so the only remaining variable in contract talks is the rate. Or incentives for the CFO or medical director reward closing value-based contracts over contribution per provider, in which case discounting is exactly the rational behaviour. Or rate discretion is unlimited across payer mix, and unlimited discretion is always used.
The diagnostic is the distribution. If deeper discounts cluster around contract renewal windows or at particular panels or providers, the cause is incentive and authority around cost per episode, not the base rate itself.
These three together are the signature. One on its own usually points somewhere else.
✓ Discounts deepen in the weeks before value-based contract renewals with major payers
✓ Discount levels differ sharply across similar panels or between the CFO and medical director on comparable attributed lives
✓ Sales or contracting asks for rate concessions rather than better cost-per-episode data on the attributed lives
The move that usually makes it worse. Lowering the base rate in new value-based contracts to match recent outcomes, which resets the anchor and produces the same discount off the new number within two contract cycles.
It is for you if you run or finance a healthcare provider and discounts spike at period end. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a healthcare provider. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Pricing & Revenue Optimization, one of 29 engagements the platform runs. For healthcare providers it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
Cap the discretion and pay on margin rather than on revenue. Discounting is a rational response to a quota measured in revenue with unlimited price authority attached.
No — as a deliberate, structured exchange for something you want, such as term, volume or a reference. As a reflex at the close of a negotiation, it is margin given away for nothing.
Move them at renewal with notice and a reason, and accept that some will leave. The alternative is a permanent two-tier price the rest of the market eventually discovers.
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית